News
Q1 2025 saw 210 enterprise SaaS mergers and acquisitions get done, a number on par with the 211 deals inked in Q4 2024, says ...
Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback